GSK NRT segment smokin’
This article was originally published in The Tan Sheet
Executive Summary
Nicotine replacement therapy sales advanced 14% "with all regions contributing to growth" to lead 2% OTC segment increase in the second quarter, GSK announces July 27. The firm is looking to future OTC weight-loss drug Xenical, which it acquired from Roche July 19 for $100 mil., to mirror success of smoking cessation products. Consumer Healthcare sales reached $1.44 bil., a 4% increase compared to the year-ago period; domestic sales were flat, although international sales rose 9% and European markets advanced 4%...
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.